Andrew Pollard speaking at Covid-19 press briefing

Andrew Pollard speaking at Covid-19 press briefing

Assessment

Interactive Video

Social Studies

University

Hard

Created by

Quizizz Content

FREE Resource

The transcript discusses the promising results of a vaccine study, highlighting a 90% efficacy rate in one arm of the study. The focus is on providing data to regulators for potential licensure and the importance of global distribution, especially in partnership with AstraZeneca. The vaccine can be stored at fridge temperatures, facilitating worldwide access. The ethical stance of a not-for-profit approach during the pandemic is emphasized. The transcript concludes with optimism for the future and the importance of protecting each other with new treatments.

Read more

5 questions

Show all answers

1.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What was the reported efficacy of one arm of the vaccine study?

70%

80%

90%

60%

2.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

Why is the ability to store the vaccine at fridge temperatures significant?

It shortens the development time.

It increases the vaccine's efficacy.

It allows for easier global distribution.

It reduces the cost of production.

3.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What was the approach agreed upon with AstraZeneca regarding vaccine profits during the pandemic?

To ensure a not-for-profit approach.

To maximize profits for reinvestment.

To increase prices in developed countries.

To share profits with other companies.

4.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What is the significance of the rapid development of the vaccine in 11 months?

It means the vaccine is less effective.

It suggests that the virus is not as serious.

It indicates a lack of thorough testing.

It shows the potential for quick responses to future pandemics.

5.

MULTIPLE CHOICE QUESTION

30 sec • 1 pt

What is the speaker's outlook for the next year regarding the pandemic?

Pessimistic due to slow vaccine distribution.

Optimistic due to new treatments and vaccines.

Uncertain because of regulatory challenges.

Negative because of ongoing virus mutations.